Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1974 Apr;71(4):1178–1182. doi: 10.1073/pnas.71.4.1178

In Vitro Properties of Leukocyte Dialysates Containing Transfer Factor

Michael S Ascher 1,*, William J Schneider 1, Fred T Valentine 1, H Sherwood Lawrence 1
PMCID: PMC388187  PMID: 4524630

Abstract

The chief impediment to the precise biochemical identification of transfer factor and its mechanism of action has been the lack of a reproducible in vitro assay. We now report on a method by which dialysates containing transfer factor of proven in vivo potency can convert nonimmune lymphocytes to immune responsiveness in vitro, as reflected by antigen-triggered lymphocyte proliferation. However, “water-dialyzed transfer factor” (TFD) prepared for in vivo use by the conventional method of dialysis against large volumes of water exhibits diminished activity in vitro and is frequently toxic to lymphocyte cultures. This problem can be avoided by dialysis of transfer factor into tissue culture medium. When this precaution is taken, such “media-dialyzed transfer factor” (TFDM) causes nonimmune lymphocytes to respond to antigen by an increment of thymidine incorporation that ranges from 2 to 25 times that of such cells cultured with antigen alone. This response is generally observed only in the presence of those antigens to which the TFDM donor expresses delayed cutaneous reactivity and is distinguishable from nonspecific adjuvant effects.

Keywords: delayed hypersensitivity, cellular immunity, lymphocyte transformation

Full text

PDF
1178

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adler W. H., Takiguchi T., Marsh B., Smith R. T. Cellular recognition by mouse lymphocytes in vitro. I. Definition of a new technique and results of stimulation by phytohemagglutinin and specific antigens. J Exp Med. 1970 Jun 1;131(6):1049–1078. doi: 10.1084/jem.131.6.1049. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Arala-Chaves M. P., Lebacq E. G., Heremans J. F. Fractionation of human leukocyte extracts transferring delayed hypersensitivity to tuberculin. Int Arch Allergy Appl Immunol. 1967;31(4):353–365. doi: 10.1159/000229881. [DOI] [PubMed] [Google Scholar]
  3. Ballow M., Dupont B., Good R. A. Autoimmune hemolytic anemia in Wiskott-Aldrich syndrome during treatment with transfer factor. J Pediatr. 1973 Nov;83(5):772–780. doi: 10.1016/s0022-3476(73)80368-3. [DOI] [PubMed] [Google Scholar]
  4. Baram P., Mosko M. M. A dialysable fraction from tuberculin-sensitive human white blood cells capable of inducing tuberculin-delayed hypersensitivity in nagative recipients. Immunology. 1965 May;8(5):461–474. [PMC free article] [PubMed] [Google Scholar]
  5. Brandes L. J., Galton D. A., Wiltshaw E. New approach to immunotherapy of melanoma. Lancet. 1971 Aug 7;2(7719):293–295. doi: 10.1016/s0140-6736(71)91336-5. [DOI] [PubMed] [Google Scholar]
  6. Brandriss M. W. Attempt to transfer contact hypersensitivity in man with dialysate of peripheral leukocytes. J Clin Invest. 1968 Sep;47(9):2152–2157. doi: 10.1172/JCI105901. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bullock W. E., Fields J. P., Brandriss M. W. An evaluation of transfer factor as immunotherapy for patients with lepromatous leprosy. N Engl J Med. 1972 Nov 23;287(21):1053–1059. doi: 10.1056/NEJM197211232872101. [DOI] [PubMed] [Google Scholar]
  8. Chess L., Levy C., Schmukler M., Smith K., Mardiney M. R., Jr The effect of synthetic polynucleotides on immunologically induced tritiated thymidine incorporation. Amplification of response. Transplantation. 1972 Dec;14(6):748–755. doi: 10.1097/00007890-197212000-00013. [DOI] [PubMed] [Google Scholar]
  9. Fireman P., Boesman M., Haddad Z. H., Gitlin D. Passive transfer of tuberculin reactivity in vitro. Science. 1967 Jan 20;155(3760):337–338. doi: 10.1126/science.155.3760.337. [DOI] [PubMed] [Google Scholar]
  10. Graybill J. R., Silva J., Jr, Alford R. H., Thor D. E. Immunologic and clinical improvement of progressive coccidioidomycosis following administration of transfer factor. Cell Immunol. 1973 Jul;8(1):120–135. doi: 10.1016/0008-8749(73)90099-3. [DOI] [PubMed] [Google Scholar]
  11. Griscelli C., Revillard J. P., Betuel H., Herzog C., Touraine J. L. Transfer factor therapy in immuno-deficiencies. Biomedicine. 1973 May;18(3):220–227. [PubMed] [Google Scholar]
  12. Kirkpatrick C. H., Rich R. R., Smith T. K. Effect of transfer factor on lymphocyte function in anergic patients. J Clin Invest. 1972 Nov;51(11):2948–2958. doi: 10.1172/JCI107119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. LAWRENCE H. S. The transfer in humans of delayed skin sensitivity to streptococcal M substance and to tuberculin with disrupted leucocytes. J Clin Invest. 1955 Feb;34(2):219–230. doi: 10.1172/JCI103075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Lawrence H. S. Transfer factor. Adv Immunol. 1969;11:195–266. doi: 10.1016/s0065-2776(08)60480-0. [DOI] [PubMed] [Google Scholar]
  15. Lawrence H. S., Valentine F. T. Transfer factor in delayed hypersensitivity. Ann N Y Acad Sci. 1970 Feb 13;169(1):269–287. doi: 10.1111/j.1749-6632.1970.tb55996.x. [DOI] [PubMed] [Google Scholar]
  16. Levin A. S., Spitler L. E., Fudenberg H. H. Transfer factor therapy in immune deficiency states. Annu Rev Med. 1973;24:175–208. doi: 10.1146/annurev.me.24.020173.001135. [DOI] [PubMed] [Google Scholar]
  17. LoBuglio A. F., Neidhart J. A., Hilberg R. W., Metz E. N., Balcerzak S. P. The effect of transfer factor therapy on tumor immunity in alveolar soft part sarcoma. Cell Immunol. 1973 Apr;7(1):159–165. doi: 10.1016/0008-8749(73)90192-5. [DOI] [PubMed] [Google Scholar]
  18. Moulias R., Goust J. M., Reinert P., Fournel J. J., Deville-Chabrolle A., Duong N., Muller-Berat C. N., Berthaux P. Facteur de transfert de l'immunitè cellulaire. Essais therapeutiques prèliminaires au cours des dèficits immunitaires spècifiques d'un antigéne en clinique humaine. Nouv Presse Med. 1973 May 19;2(20):1341–1344. [PubMed] [Google Scholar]
  19. Pabst H. F., Swanson R. Successful treatment of candidiasis with transfer factor. Br Med J. 1972 May 20;2(5811):442–443. doi: 10.1136/bmj.2.5811.442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. RAPAPORT F. T., DAUSSET J., CONVERSE J. M., LAWRENCE H. S. BIOLOGICAL AND ULTRASTRUCTURAL STUDIES OF LEUCOCYTE FRACTIONS AS TRANSPLANTATION ANTIGENS IN MAN. Transplantation. 1965 Jul;3:490–500. doi: 10.1097/00007890-196507000-00004. [DOI] [PubMed] [Google Scholar]
  21. Schulking M. L., Adler W. H., 3rd, Altemeier W. A., 3rd, Ayoub E. M. Transfer factor in the treatment of a case of chronic mucocutaneous candidiasis. Cell Immunol. 1972 Apr;3(4):606–615. doi: 10.1016/0008-8749(72)90122-0. [DOI] [PubMed] [Google Scholar]
  22. Valentine F. T., Lawrence H. S. Cell-mediated immunity. Adv Intern Med. 1971;17:51–93. [PubMed] [Google Scholar]
  23. Whitcomb M. E., Rocklin R. E. Transfer factor therapy in a patient with progressive primary tuberculosis. Ann Intern Med. 1973 Aug;79(2):161–166. doi: 10.7326/0003-4819-79-2-161. [DOI] [PubMed] [Google Scholar]
  24. Wybran J., Levin A. S., Spitler L. E., Fudenberg H. H. Rosette-forming cells, immunologic deficiency diseases and transfer factor. N Engl J Med. 1973 Apr 5;288(14):710–713. doi: 10.1056/NEJM197304052881405. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES